Technical / White Paper

Simpler and Faster Viral Vector Production Scale-Up

Format: PDF file | Document type: Technical / White Paper | Promoted Content

This content is provided by ATMI Life Science, and any views and opinions expressed do not necessarily reflect those of www.biopharma-reporter.com

ATMI

Discover how to efficiently produce wild-type or recombinant viruses to be used as vaccines and human gene therapy vectors. Learn more about results achieved for the production of AAV and a paramyxovirus in the Integrity®​ iCELLis®​ bioreactor developed by ATMI LifeSciences.​ These results indicated titer for AAV of 5.108 vg/cm² in the small scale iCELLis (versus 3.108 vg/cm²  in 5-layer stack) and 0.5-1 log titer for paramyxovirus (versus tissue culture flask). Results of transient transfection processes showed similar transfection levels in iCELLis than in the stack​.

Related resources from ATMI Life Science

Supplier info centre